Desk screen

Desk Screen Assessment

Manuscript Summary

This is a neuroscience research paper investigating the molecular mechanism by which TDP-43 (TAR DNA/RNA-binding protein 43 kDa) loses nuclear localization in amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases. The authors demonstrate that reduced proteasome activity—which occurs with aging and in ALS—triggers acetylation of lysine 82 within TDP-43's classical nuclear localization sequence (cNLS), disrupting its binding to importin-α1 and causing cytoplasmic accumulation. They validate this mechanism in human neurons and detect K82 acetylation in postmortem motor cortex from sporadic ALS patients.

Scope Assessment

In Scope for In Silico: Yes. This is original empirical research with a clear mechanistic claim, employing multiple complementary methods (cell biology, mass spectrometry, molecular binding assays, immunology, postmortem tissue analysis). The work is presented as a complete research manuscript with checkable claims.

Not a desk-reject category: The work is not a clinical trial, diagnostic guidance, or treatment recommendation. The central evidence is presented in the manuscript and supplementary figures; key materials (antibodies, cell lines, plasmids) are described or will be deposited.

Threshold Issues

1. Completeness and Intelligibility: The manuscript is well-structured, clearly written, and complete. Methods are detailed. Figures and supplementary figures are extensive and support the narrative. No fundamental unintelligibility.

2. Fundamental Flaws: No obvious fatal flaws are apparent on first reading:

• The experimental logic is sound: reduced proteasome activity → TDP-43 mislocalization → loss of nuclear function (stathmin-2 splicing defect)
• The mechanism is tested at multiple levels: whole-cell localization, protein-protein interaction, peptide binding, point mutations, postmortem tissue
• Controls are appropriate (FUS as a control for specificity; PY-NLS swap as a rescue; multiple proteasome inhibitors)
• The postmortem finding (K82 acetylation in all 6 sALS samples, absent in 4 controls) is noteworthy, though sample sizes are small

3. Evidence-Claim Alignment: The central claim—that K82 acetylation initiates TDP-43 nuclear loss of function—is reasonably well supported:

• K82Q (acetylation mimic) abolishes nuclear import and importin-α1 binding
• K82R (lysine-to-arginine) also causes mislocalization, suggesting lysine itself is critical
• Actual K82 acetylation is detected in sALS tissue
• The mechanism is demonstrated in human neurons, not just cell lines

Caveats: The acetylation is detected in both soluble and insoluble fractions of sALS tissue (suggesting it may not be the sole initiating event), and the variability among sALS samples is acknowledged. These are presented honestly and do not invalidate the core claim.

4. Methodological Soundness: Methods appear rigorous:

• Mass spectrometry with high peptide coverage (98.3%)
• Quantitative TMT proteomics for nuclear proteome
• Multiple independent approaches to validate K82 importance (mutagenesis, peptide binding, co-IP)
• Generation and validation of acetylation-specific antibodies
• Live-cell imaging with kinetic data

Minor note: Sample sizes for postmortem tissue are small (n=4 controls, n=6 sALS), but this is typical for human neuropathology studies and is not a desk-reject issue.

5. Reproducibility: Plasmids will be deposited to Addgene. Cell lines and protocols are described. Antibodies are custom-generated but the epitope and validation are described. Mass spectrometry data handling is detailed. Sufficient for independent evaluation.

6. Novelty and Contribution: The work advances understanding of TDP-43 proteinopathy by:

• Identifying a specific post-translational modification (K82 acetylation) that triggers nuclear loss
• Linking age-related proteasome decline to TDP-43 mislocalization
• Demonstrating the mechanism in human neurons and validating it in patient tissue
• Suggesting acetylation (reversible via deacetylases) as a therapeutic target

This is a solid mechanistic contribution, not merely incremental.

Potential Concerns for Reviewers (Not Desk-Reject Issues)

• Causality in sALS tissue: The detection of K82 acetylation in sALS does not prove it is the initiating event; it could be secondary. The authors acknowledge this and note that acetylation appears earlier than phosphorylation, but causality in human disease remains inferential.
• Generalizability: The work focuses on K82 acetylation; whether this mechanism applies to other TDP-43 proteinopathies (FTD, LATE, AD) is noted as an open question.
• Functional consequence: While loss of nuclear TDP-43 is shown to disrupt stathmin-2 splicing, the downstream pathological consequences in neurons are not fully explored.

These are appropriate topics for peer review, not grounds for desk rejection.

Venue Fit

In Silico's scope includes "empirical, theoretical, computational and methodological work" in "any discipline." This is empirical neuroscience research with clear, testable claims. The review will be public and the work is suitable for scrutiny by both specialists and adjacent researchers (e.g., cell biologists, proteomics experts, neurodegenerative disease researchers).

---

DESK DECISION: proceed

This manuscript meets the threshold for full review. It presents sound, well-executed research with a clear mechanistic claim supported by multiple lines of evidence. While there are appropriate questions for peer review (particularly regarding causality in human disease and generalizability), there are no fundamental flaws or scope violations that warrant desk rejection. The work is complete, intelligible, and suitable for the In Silico review process.